CRDF Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.71M
Średni wolumen	1.96M
Kapitalizacja rynkowa	154.75M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.72
ATR14	$0.00800 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Levine James E.	Buy	205 008	Stock Options
2024-03-07	Kabbinavar Fairooz	Buy	205 008	Stock Options
2024-03-07	Smeal Tod	Buy	205 008	Stock Options
2024-03-07	Erlander Mark	Buy	510 000	Stock Options
2023-12-19	Pace Gary W	Buy	30 000	Common Stock

INSIDER POWER
82.11
Last 96 transactions
Buy: 6 518 913 \| Sell: 700 088

Wolumen Korelacja

Długi: -0.04 (neutral)

Krótki: -0.62 (weak negative)

Signal:(50.25) Neutral

Cardiff Oncology Inc Korelacja

10 Najbardziej pozytywne korelacje
EBAY	0.964
CPRT	0.963
XLRN	0.96
MSTR	0.96
DAX	0.958
DWAC	0.956
GRMN	0.955
CRAI	0.953
FDT	0.953
BWMX	0.952

10 Najbardziej negatywne korelacje
VORB	-0.942
TWKS	-0.938
PEAR	-0.934
SMSI	-0.934
TEDU	-0.923
UONE	-0.919
TTEC	-0.918
QNRX	-0.915
BRQS	-0.915
BMBL	-0.914

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cardiff Oncology Inc Korelacja - Waluta/Towar

-0.16
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.03
( neutral )

-0.35
( neutral )

0.14
( neutral )

Cardiff Oncology Inc Finanse

Annual	2023
Przychody:	$488 000
Zysk brutto:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2023
Przychody:	$488 000
Zysk brutto:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2022
Przychody:	$386 000
Zysk brutto:	$186 000 (48.19 %)
EPS:	$-0.860

FY	2021
Przychody:	$359 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.